GlassScriptPhysician profile
Alexander Norton
NPI 1750331146
$1,862.25
in general payments reported to CMS, 2019-2025
26 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $181 · 2021: $201 · 2022: $270 · 2023: $228 · 2024: $240 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.25 | 2019-2023 | |
| Welch Allyn | $299.00 | 2019 | |
| Hologic Sales and Service, LLC | $143.35 | 2020-2025 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $105.21 | 2020-2022 | |
| Pfizer INC. | $101.52 | 2019-2021 | |
| Sage Therapeutics, LLC | $98.17 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $97.41 | 2024 | Veozah |
| Mayne Pharma Commercial LLC | $87.58 | 2022-2025 | |
| Organon LLC | $85.09 | 2022-2024 | Nexplanon |
| Daiichi Sankyo INC. | $66.99 | 2019-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $43.69 | 2023-2025 | |
| Vertical Pharmaceuticals, LLC | $39.56 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $31.22 | 2023-2024 | Myfembree |
| Allergan, INC. | $31.09 | 2019 | |
| Avion Pharmaceuticals | $30.06 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $28.47 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $26.82 | 2023 | Bd Onclarity |
| Pharmacosmos Therapeutics INC. | $26.58 | 2024 | Monoferric |
| Axonics, INC. | $23.70 | 2023 | Axonics, Bulkamid |
| Abbott Laboratories | $23.57 | 2023 | Proclaim |
| Supernus Pharmaceuticals, INC. | $21.45 | 2025 | Qelbree |
| Minerva Surgical, INC | $20.02 | 2025 | |
| Olympus America INC. | $18.00 | 2024 | Olympus |
| Merck Sharp & Dohme LLC | $15.19 | 2019 | |
| Myovant Sciences INC. | $14.52 | 2022 | |
| Coopersurgical, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Norton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.